What the FDA sees that doctors and patients may never know
Steve Woloshin and Lisa Schwartz of the Dartmouth Institute for Health Policy and Clinical Practice publish an important perpective piece, "Lost in Transmission -- FDA Drug Information That Never Reaches Clinicians," in this week's New England Journal of Medicine . It's about how "critical information that the FDA has at the time of drug approval may fail to make its way into the drug label and relevant journal articles." Examples they write about: sleeping pills Lunesta and Rozerem.